SI-BONE, Inc.

NasdaqGM SIBN

SI-BONE, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024: -16.64%

SI-BONE, Inc. Return on Capital Employed (ROCE) is -16.64% for the Trailing 12 Months (TTM) ending September 30, 2024, a 27.74% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

SI-BONE, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -23.03%, a 42.08% change year over year.
SI-BONE, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -39.76%, a -72.89% change year over year.
SI-BONE, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -23.00%, a 17.98% change year over year.
SI-BONE, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -28.04%, a -13.06% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGM: SIBN

SI-BONE, Inc.

CEO	Ms. Laura A. Francis MBA
IPO Date	Oct. 17, 2018
Location	United States
Headquarters	471 El Camino Real
Employees	344
Sector	Technology
Industries 3D Printing Hardware & Electronics Medical Instruments Robotics

Description

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Key trends

Past 5 years